Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment




Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment

$250,000 top award goes to Connor Hill in America’s longest running and most distinguished science and math competition

TARRYTOWN, N.Y. and WASHINGTON, March 10, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Connor Hill, 17, of State College, Pennsylvania, won the top award of $250,000 in the 2026 Regeneron Science Talent Search (STS), the U.S.’s oldest and most prestigious science and math competition for high school seniors.

Key Takeaways:

• This year marks the 85th anniversary of the Science Talent Search and Regeneron’s 10^th year as the title sponsor; Regeneron is extending its title sponsorship through 2036, pledging $150 million to fuel the next generation of science and technology leaders.
• Forty finalists were honored at the National Building Museum in Washington, D.C., receiving more than $1.8 million in awards recognizing groundbreaking research, exceptional analytical rigor, exceptional problem-solving skills and potential to shape the future of STEM.
• Top Three Winners:
  
  • Connor Hill, 17, of State College, Pennsylvania won first place and $250,000 for discovering a way to identify all the possible “noble polyhedra,” highly symmetric shapes with flat sides and straight edges. He wrote a computer program to do the computations and proved there are two infinite families of noble polyhedra, as well as 146 isolated examples.

• • Second place and $175,000 went to Edward Kang, 17, of Hackensack, New Jersey for using retinal images to train AI models on subtle patterns linked to autism and attention-deficit/hyperactivity disorder to create a screening tool called RetinaMind. He also created retinal cell models to study gene changes that may help explain why these differences occur.
  • Third place and $150,000 went to Iris Shen, 17, of The Woodlands, Texas, for testing a potential cancer drug in clams to see if they could serve as an animal model for blood cancer drug discovery. In the clams, the drug had a similar effect to what researchers observe in human cells. She also tested a mix of other potential cancer drugs, which slowed the clams’ tumor growth.

• Media Resources:
  • High-resolution photos, winner bios, project summaries, b-roll, and video interviews are available in the 2026 Regeneron Science Talent Search Media Kit: https://www.societyforscience.org/2026-regeneron-science-talent-search-media-kit
  • Media may also access the full list of 40 finalists and detailed project descriptions at: https://www.societyforscience.org/regeneron-sts/2026-student-finalists/
  • The Science Talent Search represents a long-term commitment to the next generation of scientific leadership. It supports students’ educational pursuits and research while recognizing young scientists whose intellectual rigor and bold thinking position them to shape the future of innovation.
  • Together, all 40 finalists join a distinguished group of Science Talent Search alumni, many of whom have gone on to achieve world-changing careers in STEM, including earning esteemed honors such as 13 Nobel Laureates, 23 MacArthur Fellowships and 14 winners of the National Medal of Science.

“Congratulations to the winners of this year’s Regeneron Science Talent Search,” said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News. “Their bold vision and perseverance reveal what the next generation of problem solvers truly looks like—and why our future is in capable hands. Their creativity, ambition and courage to confront the world’s toughest challenges are exactly what this moment demands.”

The Regeneron Science Talent Search is committed to providing a national platform for high school seniors to showcase original, innovative STEM research that proposes novel solutions to real-world issues. Finalists are evaluated for their scientific rigor, originality, critical thinking, leadership potential, and commitment to creating meaningful impact in crucial STEM fields.

“Congratulations to the winners of the 2026 Regeneron Science Talent Search, and to all the finalists who participated in this year’s competition. These students represent exactly the kind of extraordinary talent scientific progress depends on,” said George D. Yancopoulos, M.D., Ph.D., co-Founder, Board co-Chairman, President and Chief Scientific Officer of Regeneron and a 1976 Science Talent Search winner. “From my own experience as a Science Talent Search winner, I know the transformative power of this competition. That’s why Regeneron is deepening our commitment and extending our title sponsorship for another decade. Through our support of Science Talent Search and our title sponsorship of the Regeneron International Science Fair, the world’s largest high school science competition, we will invest more than $300 million from 2017 to 2036. We may never know where the next great scientific leader will come from, but we do know it’s our responsibility to find that talent, fuel it, and give it every chance to change the world.”

Other top honors from the competition include:

• Fourth Place and $100,000: Rachel Chen, 18, of Los Angeles, California for developing a concrete, visual way to describe systems of many quantum particles using Temperley-Lieb diagrams, expanding on a 1997 finding. Rachel illustrated how a magnetic field influences the entire quantum system using these simple point-and-line diagrams.
• Fifth Place and $90,000: Jerry Xu, 17, of Lexington, Massachusetts for building an AI program that compresses the features of protein molecules into strings of numbers. He showed that his model enabled a more efficient comparison of protein structure without the loss of important features. This could speed up genetic research and drug discovery.
• Sixth Place and $80,000: Leanne Fan, 18, of San Diego, California for building a device to simulate microgravity in order to study how wounds heal in space. With the device, she tested red light on injured flatworms and found that it sped up tissue regeneration by 95.2%. She also found that red light treatment speeds up wound repair in human models in normal gravity.
• Seventh Place and $70,000: Claire Jiang, 18, of Wyckoff, New Jersey for developing a cellular model of juvenile idiopathic arthritis (JIA). She treated cells used to study rheumatoid arthritis with bone morphogenetic protein 4, a protein linked to JIA joint damage. Her experiments showed they acted like JIA cells in their growth and gene expression.
• Eighth Place and $60,000: Leon Wang, 17, of Stamford, Connecticut, for finding two FDA-approved drugs that may also be effective against Alzheimer’s disease. Both drugs reduce the activity of a cellular signaling pathway linked to an Alzheimer’s gene. In lab-grown brain cells, the drugs reduced signs of damage due to the pathway.
• Ninth Place and $50,000: Jonathan Du, 18, of Mountain View, California for investigating the unrestricted finite factorization property. Factorization breaks down mathematical objects into simpler parts. Jonathan’s work explores complicated algebraic systems where some elements have several factorizations, and others do not factor at all.
• Tenth Place and $40,000: Seth Nabat, 18, of Winnetka, California for building a machine learning program to quickly and accurately track particle collisions without sacrificing accuracy by favoring symmetry. Seth’s program uses an unconstrained network to catch errors, and another network to find patterns in them.
• Colin Jie Chu, 18, of Palo Alto, California was named the Seaborg Award winner and selected to speak on behalf of the Regeneron Science Talent Search Class of 2026. The 40 finalists chose Colin as the person who best exemplifies their class and the legacy of nuclear chemist Glenn T. Seaborg, who won the Nobel Prize for Chemistry in 1951 and served on the Society’s Board of Trustees for 30 years.
• The remaining 30 finalists received $25,000 each. In total, Regeneron awarded $3.1 million in awards, including $2,000 to each top scholar and their school. Since the start of Regeneron’s sponsorship in 2017 through this year’s competition, Regeneron and the Society have engaged and inspired more than 20,000 of the nation’s top young scientists, recognized 3,000 as Regeneron scholars, and awarded over $31 million in prizes.

Resources:

• 2026 Winner Media Kit (photos, bios, research summaries, b-roll, video)
• Virtual Project Showcase (All 40 finalist projects)
• Full List of 40 Finalists
• Top 300 Scholars
• Notable STS Alumni

What is the Regeneron Science Talent Search?

The Regeneron Science Talent Search, a program of Society for Science since 1942, is the United States’ oldest and most prestigious science and math competition for high school seniors. This year, more than 2,600 students submitted original research in critical scientific fields and were judged by leading experts. Unique among high school competitions in the U.S. and globally, the Regeneron Science Talent Search identifies and supports the U.S.’s most promising future leaders in science as they develop innovative solutions to solve significant global challenges through rigorous research and discoveries. The program provides students with a national stage to present new ideas and challenge conventional ways of thinking.

For over eight decades, the Science Talent Search has rewarded talented high school seniors who dedicate countless hours to original research projects and present their results in rigorous reports that resemble graduate school theses. Collectively, STS alumni have received millions of dollars in scholarships and gone on to be awarded Nobel Prizes, Fields Medals, MacArthur Fellowships and numerous other accolades.

What is Regeneron’s role?

For Regeneron, the Science Talent Search is a deeply personal commitment, as its co-Founders George D. Yancopoulos, M.D., Ph.D. and Leonard S. Schleifer, M.D., Ph.D. began their scientific careers as Science Talent Search participants. In 2017, Regeneron became the third long-term sponsor of the Science Talent Search, succeeding Westinghouse and Intel, with a 10-year, $100 million commitment to help reward and celebrate the best and brightest young minds. Since the beginning of this enduring sponsorship, through this year’s Science Talent Search, Regeneron and the Society have engaged and inspired more than 20,000 of the nation’s top young scientists, recognized 3,000 as Regeneron Scholars, and awarded over $31 million in prizes. In February 2026, the company renewed its sponsorship for another decade, increasing its investment by 50%, pledging an additional $150 million. Regeneron is also the title sponsor of the Regeneron International Science and Engineering Fair (ISEF), a program of the Society and the world’s largest high school science competition. Regeneron’s support for these two premier programs totals more than $300 million from 2017 to 2036.

Learn more at https://www.societyforscience.org/regeneron-sts/ or www.regeneron.com/STEM

What is Society for Science?

Society for Science is a champion for science, dedicated to promoting the understanding and appreciation of science and the vital role it plays in human advancement. Established in 1921, Society for Science is best known for its award-winning journalism through Science News and Science News Explores, its world-class science research competitions for students, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair and the Thermo Fisher Scientific Junior Innovators Challenge, and its STEM Outreach programming that seeks to ensure that all students have an opportunity to pursue a career in STEM. A 501(c)(3) membership organization, Society for Science is committed to inform, educate and inspire.

Learn more at www.societyforscience.org and follow us on Facebook, X, Instagram, and LinkedIn.

What is Regeneron?

Regeneron is a leading biotechnology company that invents, develops, and commercializes potentially life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious diseases, to foster a culture of integrity and excellence, and to build sustainable communities. Our most significant philanthropic investments are in science education, a commitment we call STEM-Fueled™ – our collection of programs and partnerships, including the Regeneron Science Talent Search (STS) and the Regeneron International Science and Engineering Fair (ISEF), that fuel future scientific innovators to pursue bold ideas and advance world-changing solutions. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro bono, and matching gift programs. We are proud to be recognized on the Dow Jones Sustainability World Index and the Civic 50 list of the most “community-minded” companies in the United States.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Media Contacts:
Gayle Kansagor, Society for Science
703-489-1131, gkansagor@societyforscience.org

Tina Parisi Tuttle, Regeneron
973-975-9357, tina.parisituttle@regeneron.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a58bf3ac-2d0f-41db-9885-3340508eac33

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering




Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering

NEW YORK and WALTHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the pricing of its previously announced upsized underwritten public offering of 7,313,582 shares of its common stock at a public offering price per share of $81.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 402,468 shares of its common stock at a public offering price of $80.999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. The aggregate gross proceeds to Dianthus from the offering are expected to be approximately $625 million before deducting underwriting discounts and commissions and other offering expenses and advisory fees payable by Dianthus, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on March 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Dianthus has granted the underwriters a 30-day option to purchase up to an additional 1,157,407 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the securities are being offered by Dianthus.

Dianthus intends to use the net proceeds from this offering to advance the Company’s clinical and preclinical development activities, commercial readiness activities as well as for working capital and general corporate purposes.

Jefferies, TD Cowen, Evercore ISI, Stifel, Guggenheim Securities and William Blair are acting as joint book-running managers for the offering. LifeSci Capital is acting as Dianthus’ financial advisor.

The offering is being made pursuant to a shelf registration statement on Form S-3 relating to the securities that was previously filed with the Securities and Exchange Commission (“SEC”) and declared effective on January 30, 2026 and a related registration statement that was filed with the SEC on March 10, 2026 pursuant to Rule 462(b) under the Securities Act of 1933, as amended (and became automatically effective upon filing). This offering is being made only by means of a written prospectus, including a prospectus supplement, forming a part of an effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov. A copy of the final prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov, and, when available, may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at (800) 621-0687 or by email at prospectus@williamblair.com.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, express or implied statements regarding Dianthus’ expectations regarding the consummation of the offering, the satisfaction of customary closing conditions with respect to the offering and the potential value and clinical benefit of the Company’s product candidates. The words “opportunity,” “potential,” “milestones,” “runway,” “will,” “anticipate,” “achieve,” “near-term,” “catalysts,” “pursue,” “pipeline,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “predict,” “project,” “should,” “strive,” “would,” “aim,” “target,” “commit,” and similar expressions (including the negatives of these terms or variations of them) generally identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.

Actual results could differ materially from those included in the forward-looking statements due to various factors, risks and uncertainties, including, but not limited to, that preclinical testing of claseprubart and DNTH212 and data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials, that the development of claseprubart, DNTH212 or the Company’s other compounds may take longer and/or cost more than planned, that the Company or its partner may be unable to successfully complete the clinical development of the Company’s compounds, that the Company or its partner may be delayed in initiating, enrolling or completing its planned clinical trials, and that the Company’s compounds may not receive regulatory approval or become commercially successful products. These and other risks and uncertainties are identified under the heading “Risk Factors” included in the Company’s Annual Report on Form 10-K for the period ended December 31, 2025, and other filings that the Company has made and may make with the SEC in the future. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved.

The forward-looking statements in this press release speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Dianthus undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering




Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

VANCOUVER, British Columbia and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced the pricing of its upsized underwritten public offering of 10,526,317 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 877,194 common shares pursuant to its existing shelf registration statement. The common shares are being offered at a public offering price of $57.00 per common share and the pre-funded warrants are being offered at a price of $56.9999 per pre-funded warrant. The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, are expected to be approximately $650.0 million. In addition, Xenon has granted to the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,710,526 common shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about March 12, 2026, subject to the satisfaction of customary closing conditions.

J.P. Morgan, Jefferies, TD Cowen, Stifel, RBC Capital Markets, and William Blair are acting as joint book-running managers for the offering. Baird is acting as lead manager for the offering.

An automatically effective shelf registration statement relating to the securities offered in the public offering described above was filed with the Securities and Exchange Commission (the “SEC”) on August 9, 2024. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, telephone: (415) 364-2720 or by emailing syndprospectus@stifel.com; RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, New York, NY 10281, by telephone at (877) 822-4089, or by email at equityprospectus@rbccm.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at (800) 621-0687 or by email at prospectus@williamblair.com.

No securities are being offered or sold, directly or indirectly, in Canada or to any resident of Canada.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact and include statements regarding the anticipated closing of the public offering. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to, uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all; the impact of unstable economic conditions in the general domestic and global economic markets; adverse conditions from geopolitical events; as well as the other risks identified in our filings with the SEC and the securities commissions in British Columbia, Alberta and Ontario. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent K_V7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including K_V7 and Na_V1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts.

Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.

Investor Contact:
Tucker Kelly
Chief Financial Officer
Email: investors@xenon-pharma.com

Source: Xenon Pharmaceuticals Inc.

Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment




Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment

$250,000 top award goes to Connor Hill in America’s longest running and most distinguished science and math competition

TARRYTOWN, N.Y. and WASHINGTON, March 10, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Connor Hill, 17, of State College, Pennsylvania, won the top award of $250,000 in the 2026 Regeneron Science Talent Search (STS), the U.S.’s oldest and most prestigious science and math competition for high school seniors.

Key Takeaways:

• This year marks the 85th anniversary of the Science Talent Search and Regeneron’s 10^th year as the title sponsor; Regeneron is extending its title sponsorship through 2036, pledging $150 million to fuel the next generation of science and technology leaders.
• Forty finalists were honored at the National Building Museum in Washington, D.C., receiving more than $1.8 million in awards recognizing groundbreaking research, exceptional analytical rigor, exceptional problem-solving skills and potential to shape the future of STEM.
• Top Three Winners:
  • Connor Hill, 17, of State College, Pennsylvania won first place and $250,000 for discovering a way to identify all the possible “noble polyhedra,” highly symmetric shapes with flat sides and straight edges. He wrote a computer program to do the computations and proved there are two infinite families of noble polyhedra, as well as 146 isolated examples.
  • Second place and $175,000 went to Edward Kang, 17, of Hackensack, New Jersey for using retinal images to train AI models on subtle patterns linked to autism and attention-deficit/hyperactivity disorder to create a screening tool called RetinaMind. He also created retinal cell models to study gene changes that may help explain why these differences occur.
  • Third place and $150,000 went to Iris Shen, 17, of The Woodlands, Texas, for testing a potential cancer drug in clams to see if they could serve as an animal model for blood cancer drug discovery. In the clams, the drug had a similar effect to what researchers observe in human cells. She also tested a mix of other potential cancer drugs, which slowed the clams’ tumor growth.

“Congratulations to the winners of this year’s Regeneron Science Talent Search,” said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News. “Their bold vision and perseverance reveal what the next generation of problem solvers truly looks like—and why our future is in capable hands. Their creativity, ambition and courage to confront the world’s toughest challenges are exactly what this moment demands.”

The Regeneron Science Talent Search is committed to providing a national platform for high school seniors to showcase original, innovative STEM research that proposes novel solutions to real-world issues. Finalists are evaluated for their scientific rigor, originality, critical thinking, leadership potential, and commitment to creating meaningful impact in crucial STEM fields.

“Congratulations to the winners of the 2026 Regeneron Science Talent Search, and to all the finalists who participated in this year’s competition. These students represent exactly the kind of extraordinary talent scientific progress depends on,” said George D. Yancopoulos, M.D., Ph.D., co-Founder, Board co-Chairman, President and Chief Scientific Officer of Regeneron and a 1976 Science Talent Search winner. “From my own experience as a Science Talent Search winner, I know the transformative power of this competition. That’s why Regeneron is deepening our commitment and extending our title sponsorship for another decade. Through our support of Science Talent Search and our title sponsorship of the Regeneron International Science Fair, the world’s largest high school science competition, we will invest more than $300 million from 2017 to 2036. We may never know where the next great scientific leader will come from, but we do know it’s our responsibility to find that talent, fuel it, and give it every chance to change the world.”

Other top honors from the competition include:

• Fourth Place and $100,000: Rachel Chen, 18, of Los Angeles, California for developing a concrete, visual way to describe systems of many quantum particles using Temperley-Lieb diagrams, expanding on a 1997 finding. Rachel illustrated how a magnetic field influences the entire quantum system using these simple point-and-line diagrams.
• Fifth Place and $90,000: Jerry Xu, 17, of Lexington, Massachusetts for building an AI program that compresses the features of protein molecules into strings of numbers. He showed that his model enabled a more efficient comparison of protein structure without the loss of important features. This could speed up genetic research and drug discovery.
• Sixth Place and $80,000: Leanne Fan, 18, of San Diego, California for building a device to simulate microgravity in order to study how wounds heal in space. With the device, she tested red light on injured flatworms and found that it sped up tissue regeneration by 95.2%. She also found that red light treatment speeds up wound repair in human models in normal gravity.
• Seventh Place and $70,000: Claire Jiang, 18, of Wyckoff, New Jersey for developing a cellular model of juvenile idiopathic arthritis (JIA). She treated cells used to study rheumatoid arthritis with bone morphogenetic protein 4, a protein linked to JIA joint damage. Her experiments showed they acted like JIA cells in their growth and gene expression.
• Eighth Place and $60,000: Leon Wang, 17, of Stamford, Connecticut, for finding two FDA-approved drugs that may also be effective against Alzheimer’s disease. Both drugs reduce the activity of a cellular signaling pathway linked to an Alzheimer’s gene. In lab-grown brain cells, the drugs reduced signs of damage due to the pathway.
• Ninth Place and $50,000: Jonathan Du, 18, of Mountain View, California for investigating the unrestricted finite factorization property. Factorization breaks down mathematical objects into simpler parts. Jonathan’s work explores complicated algebraic systems where some elements have several factorizations, and others do not factor at all.
• Tenth Place and $40,000: Seth Nabat, 18, of Winnetka, California for building a machine learning program to quickly and accurately track particle collisions without sacrificing accuracy by favoring symmetry. Seth’s program uses an unconstrained network to catch errors, and another network to find patterns in them.
• Colin Jie Chu, 18, of Palo Alto, California was named the Seaborg Award winner and selected to speak on behalf of the Regeneron Science Talent Search Class of 2026. The 40 finalists chose Colin as the person who best exemplifies their class and the legacy of nuclear chemist Glenn T. Seaborg, who won the Nobel Prize for Chemistry in 1951 and served on the Society’s Board of Trustees for 30 years.
• The remaining 30 finalists received $25,000 each. In total, Regeneron awarded $3.1 million in awards, including $2,000 to each top scholar and their school. Since the start of Regeneron’s sponsorship in 2017 through this year’s competition, Regeneron and the Society have engaged and inspired more than 20,000 of the nation’s top young scientists, recognized 3,000 as Regeneron scholars, and awarded over $31 million in prizes.

Resources:

• 2026 Winner Media Kit (photos, bios, research summaries, b-roll, video)
• Virtual Project Showcase (All 40 finalist projects)
• Full List of 40 Finalists
• Top 300 Scholars
• Notable STS Alumni

What is the Regeneron Science Talent Search?

The Regeneron Science Talent Search, a program of Society for Science since 1942, is the United States’ oldest and most prestigious science and math competition for high school seniors. This year, more than 2,600 students submitted original research in critical scientific fields and were judged by leading experts. Unique among high school competitions in the U.S. and globally, the Regeneron Science Talent Search identifies and supports the U.S.’s most promising future leaders in science as they develop innovative solutions to solve significant global challenges through rigorous research and discoveries. The program provides students with a national stage to present new ideas and challenge conventional ways of thinking.

For over eight decades, the Science Talent Search has rewarded talented high school seniors who dedicate countless hours to original research projects and present their results in rigorous reports that resemble graduate school theses. Collectively, STS alumni have received millions of dollars in scholarships and gone on to be awarded Nobel Prizes, Fields Medals, MacArthur Fellowships and numerous other accolades.

What is Regeneron’s role?

For Regeneron, the Science Talent Search is a deeply personal commitment, as its co-Founders George D. Yancopoulos, M.D., Ph.D. and Leonard S. Schleifer, M.D., Ph.D. began their scientific careers as Science Talent Search participants. In 2017, Regeneron became the third long-term sponsor of the Science Talent Search, succeeding Westinghouse and Intel, with a 10-year, $100 million commitment to help reward and celebrate the best and brightest young minds. Since the beginning of this enduring sponsorship, through this year’s Science Talent Search, Regeneron and the Society have engaged and inspired more than 20,000 of the nation’s top young scientists, recognized 3,000 as Regeneron Scholars, and awarded over $31 million in prizes. In February 2026, the company renewed its sponsorship for another decade, increasing its investment by 50%, pledging an additional $150 million. Regeneron is also the title sponsor of the Regeneron International Science and Engineering Fair (ISEF), a program of the Society and the world’s largest high school science competition. Regeneron’s support for these two premier programs totals more than $300 million from 2017 to 2036.

Learn more at https://www.societyforscience.org/regeneron-sts/ or www.regeneron.com/STEM

What is Society for Science?

Society for Science is a champion for science, dedicated to promoting the understanding and appreciation of science and the vital role it plays in human advancement. Established in 1921, Society for Science is best known for its award-winning journalism through Science News and Science News Explores, its world-class science research competitions for students, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair and the Thermo Fisher Scientific Junior Innovators Challenge, and its STEM Outreach programming that seeks to ensure that all students have an opportunity to pursue a career in STEM. A 501(c)(3) membership organization, Society for Science is committed to inform, educate and inspire.

Learn more at www.societyforscience.org and follow us on Facebook, X, Instagram, and LinkedIn.

What is Regeneron?

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops, and commercializes potentially life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious diseases, to foster a culture of integrity and excellence, and to build sustainable communities. Our most significant philanthropic investments are in science education, a commitment we call STEM-Fueled™ – our collection of programs and partnerships, including the Regeneron Science Talent Search (STS) and the Regeneron International Science and Engineering Fair (ISEF), that fuel future scientific innovators to pursue bold ideas and advance world-changing solutions. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro bono, and matching gift programs. We are proud to be recognized on the Dow Jones Sustainability World Index and the Civic 50 list of the most “community-minded” companies in the United States.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Media Contacts:
Tina Parisi Tuttle, Regeneron
973-975-9357, tina.parisituttle@regeneron.com

Gayle Kansagor, Society for Science 
703-489-1131, gkansagor@societyforscience.org

Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment




Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment

$250,000 top award goes to Connor Hill in America’s longest running and most distinguished science and math competition

TARRYTOWN, N.Y. and WASHINGTON, March 10, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Connor Hill, 17, of State College, Pennsylvania, won the top award of $250,000 in the 2026 Regeneron Science Talent Search (STS), the U.S.’s oldest and most prestigious science and math competition for high school seniors.

Key Takeaways:

• This year marks the 85th anniversary of the Science Talent Search and Regeneron’s 10^th year as the title sponsor; Regeneron is extending its title sponsorship through 2036, pledging $150 million to fuel the next generation of science and technology leaders.
• Forty finalists were honored at the National Building Museum in Washington, D.C., receiving more than $1.8 million in awards recognizing groundbreaking research, exceptional analytical rigor, exceptional problem-solving skills and potential to shape the future of STEM.
• Top Three Winners:
  • Connor Hill, 17, of State College, Pennsylvania won first place and $250,000 for discovering a way to identify all the possible “noble polyhedra,” highly symmetric shapes with flat sides and straight edges. He wrote a computer program to do the computations and proved there are two infinite families of noble polyhedra, as well as 146 isolated examples.
  • Second place and $175,000 went to Edward Kang, 17, of Hackensack, New Jersey for using retinal images to train AI models on subtle patterns linked to autism and attention-deficit/hyperactivity disorder to create a screening tool called RetinaMind. He also created retinal cell models to study gene changes that may help explain why these differences occur.
  • Third place and $150,000 went to Iris Shen, 17, of The Woodlands, Texas, for testing a potential cancer drug in clams to see if they could serve as an animal model for blood cancer drug discovery. In the clams, the drug had a similar effect to what researchers observe in human cells. She also tested a mix of other potential cancer drugs, which slowed the clams’ tumor growth.

“Congratulations to the winners of this year’s Regeneron Science Talent Search,” said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News. “Their bold vision and perseverance reveal what the next generation of problem solvers truly looks like—and why our future is in capable hands. Their creativity, ambition and courage to confront the world’s toughest challenges are exactly what this moment demands.”

The Regeneron Science Talent Search is committed to providing a national platform for high school seniors to showcase original, innovative STEM research that proposes novel solutions to real-world issues. Finalists are evaluated for their scientific rigor, originality, critical thinking, leadership potential, and commitment to creating meaningful impact in crucial STEM fields.

“Congratulations to the winners of the 2026 Regeneron Science Talent Search, and to all the finalists who participated in this year’s competition. These students represent exactly the kind of extraordinary talent scientific progress depends on,” said George D. Yancopoulos, M.D., Ph.D., co-Founder, Board co-Chairman, President and Chief Scientific Officer of Regeneron and a 1976 Science Talent Search winner. “From my own experience as a Science Talent Search winner, I know the transformative power of this competition. That’s why Regeneron is deepening our commitment and extending our title sponsorship for another decade. Through our support of Science Talent Search and our title sponsorship of the Regeneron International Science Fair, the world’s largest high school science competition, we will invest more than $300 million from 2017 to 2036. We may never know where the next great scientific leader will come from, but we do know it’s our responsibility to find that talent, fuel it, and give it every chance to change the world.”

Other top honors from the competition include:

• Fourth Place and $100,000: Rachel Chen, 18, of Los Angeles, California for developing a concrete, visual way to describe systems of many quantum particles using Temperley-Lieb diagrams, expanding on a 1997 finding. Rachel illustrated how a magnetic field influences the entire quantum system using these simple point-and-line diagrams.
• Fifth Place and $90,000: Jerry Xu, 17, of Lexington, Massachusetts for building an AI program that compresses the features of protein molecules into strings of numbers. He showed that his model enabled a more efficient comparison of protein structure without the loss of important features. This could speed up genetic research and drug discovery.
• Sixth Place and $80,000: Leanne Fan, 18, of San Diego, California for building a device to simulate microgravity in order to study how wounds heal in space. With the device, she tested red light on injured flatworms and found that it sped up tissue regeneration by 95.2%. She also found that red light treatment speeds up wound repair in human models in normal gravity.
• Seventh Place and $70,000: Claire Jiang, 18, of Wyckoff, New Jersey for developing a cellular model of juvenile idiopathic arthritis (JIA). She treated cells used to study rheumatoid arthritis with bone morphogenetic protein 4, a protein linked to JIA joint damage. Her experiments showed they acted like JIA cells in their growth and gene expression.
• Eighth Place and $60,000: Leon Wang, 17, of Stamford, Connecticut, for finding two FDA-approved drugs that may also be effective against Alzheimer’s disease. Both drugs reduce the activity of a cellular signaling pathway linked to an Alzheimer’s gene. In lab-grown brain cells, the drugs reduced signs of damage due to the pathway.
• Ninth Place and $50,000: Jonathan Du, 18, of Mountain View, California for investigating the unrestricted finite factorization property. Factorization breaks down mathematical objects into simpler parts. Jonathan’s work explores complicated algebraic systems where some elements have several factorizations, and others do not factor at all.
• Tenth Place and $40,000: Seth Nabat, 18, of Winnetka, California for building a machine learning program to quickly and accurately track particle collisions without sacrificing accuracy by favoring symmetry. Seth’s program uses an unconstrained network to catch errors, and another network to find patterns in them.
• Colin Jie Chu, 18, of Palo Alto, California was named the Seaborg Award winner and selected to speak on behalf of the Regeneron Science Talent Search Class of 2026. The 40 finalists chose Colin as the person who best exemplifies their class and the legacy of nuclear chemist Glenn T. Seaborg, who won the Nobel Prize for Chemistry in 1951 and served on the Society’s Board of Trustees for 30 years.
• The remaining 30 finalists received $25,000 each. In total, Regeneron awarded $3.1 million in awards, including $2,000 to each top scholar and their school. Since the start of Regeneron’s sponsorship in 2017 through this year’s competition, Regeneron and the Society have engaged and inspired more than 20,000 of the nation’s top young scientists, recognized 3,000 as Regeneron scholars, and awarded over $31 million in prizes.

Resources:

• 2026 Winner Media Kit (photos, bios, research summaries, b-roll, video)
• Virtual Project Showcase (All 40 finalist projects)
• Full List of 40 Finalists
• Top 300 Scholars
• Notable STS Alumni

What is the Regeneron Science Talent Search?

The Regeneron Science Talent Search, a program of Society for Science since 1942, is the United States’ oldest and most prestigious science and math competition for high school seniors. This year, more than 2,600 students submitted original research in critical scientific fields and were judged by leading experts. Unique among high school competitions in the U.S. and globally, the Regeneron Science Talent Search identifies and supports the U.S.’s most promising future leaders in science as they develop innovative solutions to solve significant global challenges through rigorous research and discoveries. The program provides students with a national stage to present new ideas and challenge conventional ways of thinking.

For over eight decades, the Science Talent Search has rewarded talented high school seniors who dedicate countless hours to original research projects and present their results in rigorous reports that resemble graduate school theses. Collectively, STS alumni have received millions of dollars in scholarships and gone on to be awarded Nobel Prizes, Fields Medals, MacArthur Fellowships and numerous other accolades.

What is Regeneron’s role?

For Regeneron, the Science Talent Search is a deeply personal commitment, as its co-Founders George D. Yancopoulos, M.D., Ph.D. and Leonard S. Schleifer, M.D., Ph.D. began their scientific careers as Science Talent Search participants. In 2017, Regeneron became the third long-term sponsor of the Science Talent Search, succeeding Westinghouse and Intel, with a 10-year, $100 million commitment to help reward and celebrate the best and brightest young minds. Since the beginning of this enduring sponsorship, through this year’s Science Talent Search, Regeneron and the Society have engaged and inspired more than 20,000 of the nation’s top young scientists, recognized 3,000 as Regeneron Scholars, and awarded over $31 million in prizes. In February 2026, the company renewed its sponsorship for another decade, increasing its investment by 50%, pledging an additional $150 million. Regeneron is also the title sponsor of the Regeneron International Science and Engineering Fair (ISEF), a program of the Society and the world’s largest high school science competition. Regeneron’s support for these two premier programs totals more than $300 million from 2017 to 2036.

Learn more at https://www.societyforscience.org/regeneron-sts/ or www.regeneron.com/STEM

What is Society for Science?

Society for Science is a champion for science, dedicated to promoting the understanding and appreciation of science and the vital role it plays in human advancement. Established in 1921, Society for Science is best known for its award-winning journalism through Science News and Science News Explores, its world-class science research competitions for students, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair and the Thermo Fisher Scientific Junior Innovators Challenge, and its STEM Outreach programming that seeks to ensure that all students have an opportunity to pursue a career in STEM. A 501(c)(3) membership organization, Society for Science is committed to inform, educate and inspire.

Learn more at www.societyforscience.org and follow us on Facebook, X, Instagram, and LinkedIn.

What is Regeneron?

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops, and commercializes potentially life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious diseases, to foster a culture of integrity and excellence, and to build sustainable communities. Our most significant philanthropic investments are in science education, a commitment we call STEM-Fueled™ – our collection of programs and partnerships, including the Regeneron Science Talent Search (STS) and the Regeneron International Science and Engineering Fair (ISEF), that fuel future scientific innovators to pursue bold ideas and advance world-changing solutions. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro bono, and matching gift programs. We are proud to be recognized on the Dow Jones Sustainability World Index and the Civic 50 list of the most “community-minded” companies in the United States.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Media Contacts:
Tina Parisi Tuttle, Regeneron
973-975-9357, tina.parisituttle@regeneron.com

Gayle Kansagor, Society for Science 
703-489-1131, gkansagor@societyforscience.org

TrimX Drops Metabolism Claims Evaluated: Latest Report About TrimX Liquid Thermogenic Formula Ingredient Research & Effectiveness for Men & Women




TrimX Drops Metabolism Claims Evaluated: Latest Report About TrimX Liquid Thermogenic Formula Ingredient Research & Effectiveness for Men & Women

A 2026 consumer research report examining TrimX Drops metabolism marketing claims, liquid thermogenic formulation, ingredient-level research, and key verification considerations for adults researching weight management supplements

Lakeland, FL, March 10, 2026 (GLOBE NEWSWIRE) — This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This article is an informational overview and does not constitute medical, health, or dietary advice. All product details described below are stated as presented by the company and should be verified directly on the official website before any purchasing decision. In this report, the term “effectiveness” refers strictly to how TrimX’s marketing language describes potential outcomes. It does not indicate that the finished product has been clinically proven effective, and no published clinical trial appears to evaluate TrimX Drops as a proprietary formula.

Consumer interest in metabolism-support supplements has grown significantly in recent years, particularly products marketed as thermogenic fat-burning formulas in liquid delivery formats. Online search activity around metabolism drops, thermogenic supplements, and liquid fat-burning formulas remains high across wellness and supplement research communities — driven largely by adults over 35 who feel stuck with stubborn weight despite genuine effort with diet and exercise.

One product generating increased online searches is TrimX Drops, a liquid supplement positioned by the company as a metabolic combination intended to support metabolism, influence fat storage signals, and help manage cravings. With that visibility come real questions — and those questions are worth examining in light of the available ingredient research and the company’s published claims.

This report evaluates what the company states, what ingredient-level research supports under controlled conditions, and where gaps remain between marketing language and product-level evidence. Readers can view the current TrimX offer (official TrimX page) to review the latest product information and company-published details.

Individual results vary. Dietary supplements are not substitutes for balanced nutrition, regular physical activity, or professional medical guidance. Consult a qualified healthcare provider before starting any new supplement regimen.

What Is TrimX

TrimX is a dietary supplement sold in liquid drop form. According to the company’s website, it is produced in the United States in an FDA-registered facility using naturally-derived ingredients without harmful artificial stimulants or chemical additives. The company states that all ingredients are tested for quality and safety.

The recommended use, per the company, is one or two droppers full daily — placed in the mouth and swallowed, preferably in the morning before breakfast. The product is sold exclusively through the official website, with payments processed through CartPanda. According to the company, all purchases are one-time orders with no automatic renewals, hidden fees, or surprise charges.

The published ingredient list includes six primary active compounds: Guarana Seed Extract, Green Tea, African Mango, Raspberry Ketones, L-Carnitine, and Gymnema Leaf Extract. Each is positioned by the company as serving a distinct metabolic function within the formula.

TrimX Marketing Claims vs. What Research Supports

The company’s marketing describes TrimX as targeting what it calls the root causes of stubborn fat, persistent bloating, and uncontrolled hunger. The product page presents a narrative around metabolic slowdown and positions TrimX as a formula that works on three fronts: accelerating metabolism through thermogenics, controlling hunger through satiety-related compounds, and optimizing fat transport for energy use.

These claims reflect the product’s marketing narrative rather than conclusions from clinical trials evaluating the finished formulation. Understanding the distinction matters if you’re trying to make an informed decision.

The individual ingredients in TrimX do have varying levels of published research behind them — but that research examined specific compounds at known dosages under controlled conditions, not TrimX’s specific liquid formula as a finished product.

For example, green tea catechins (particularly EGCG) have a substantial research base. A 2009 meta-analysis in the International Journal of Obesity found that catechin-caffeine mixtures had a modest positive effect on weight management. However, effective study dosages typically involved 270 to 600 mg of EGCG daily. TrimX does not disclose the exact amount of green tea extract or EGCG per serving.

Similarly, African Mango seed extract was associated with improvements in body weight in a 2009 randomized trial published in Lipids in Health and Disease — but at a specific dosage of 150 mg twice daily. Whether TrimX provides a comparable amount is not stated on the product page.

Consumers researching TrimX online often look for information about its ingredients, metabolism-related marketing claims, and how the formula compares with existing ingredient research. What matters most here is understanding that marketing language referencing metabolic research describes ingredient-level findings, not product-level clinical outcomes verified through independent testing.

TrimX Ingredient Profile

Based on the company’s published product information, TrimX contains six active ingredients. Here is what the company describes and what published research indicates for each compound individually.

Guarana Seed Extract: The company describes this as a natural thermogenic that speeds up metabolism and provides sustained energy. Guarana contains caffeine, which has well-documented short-term effects on metabolic rate in published literature. The specific caffeine content per dropper is not disclosed.

Green Tea: The company states that green tea catechins help the body access stored fat, especially in the abdominal region. Published research supports associations between green tea catechins and fat oxidation, though effective study dosages typically exceed what a multi-ingredient liquid formula would deliver without disclosed amounts.

African Mango: The company positions this as a natural appetite suppressant that works through leptin, the satiety hormone. Published research on Irvingia gabonensis does exist, though studies used specific dosages of a characterized extract.

Raspberry Ketones: The company describes these as activating lipolysis — the process of breaking down fat. Published human research on raspberry ketones in isolation is extremely limited. Most studies have used multi-ingredient formulations, making it difficult to isolate raspberry ketone-specific effects.

L-Carnitine: The company describes this as the fat transporter that carries fatty acids to the mitochondria for energy production. L-Carnitine has a stronger published research base than most ingredients in this formula. A 2016 systematic review in Obesity Reviews found modest associations with weight loss — though study dosages typically ranged from 1,000 to 3,000 mg daily.

Gymnema Leaf Extract: The company calls this the sugar destroyer, referencing effects on glucose absorption and sweet taste perception. Gymnema sylvestre has been studied primarily for blood sugar regulation, with most evidence coming from animal models or small human trials.

The key consideration across all six ingredients is that TrimX does not disclose individual dosages per serving. Without knowing exact amounts, you cannot directly compare what is in each dropper against the dosages used in published research studies. This is not unique to TrimX — many liquid supplements use similar labeling — but it is worth factoring into your evaluation.

The Liquid Delivery Format

TrimX is marketed in liquid drop form, and the company’s materials suggest advantages over capsules or tablets. Liquid supplement formats are sometimes marketed as offering faster absorption. There is some published basis for this concept in certain contexts — but bioavailability depends on the specific compound, formulation vehicle, and individual digestive physiology.

No published study appears to evaluate TrimX’s specific liquid formula compared against alternative delivery formats for the same ingredients. The liquid format is a distinguishing feature in the supplement market, but the absorption advantage claim has not been validated for this specific product.

What Would Be Required to Prove Effectiveness

This is one of the most practical questions you can ask about any supplement. For a dietary supplement to demonstrate effectiveness through clinical evidence, the standard includes a randomized, placebo-controlled trial using the finished product at its actual dosage — with disclosed formulation, defined endpoints, and a representative study population. Results would be published in a peer-reviewed journal.

As of this writing, no published clinical trial appears to have evaluated TrimX Drops as a finished proprietary formula. The research cited in the product’s marketing pertains to individual compounds tested in isolation, often at dosages that may differ from what the liquid formula delivers. Understanding this distinction helps you make a purchasing decision based on the actual evidence landscape.

Who May Be Interested in This Type of Product

Based on the product’s positioning and ingredient profile, TrimX may be of interest to adults exploring plant-based metabolism-support supplements in liquid form as one component of a broader wellness approach that includes balanced nutrition and regular physical activity.

TrimX may align well with people who prefer liquid supplement formats over capsules, want a caffeine-containing thermogenic option with natural energy sources, or are looking for appetite management support as part of a broader dietary strategy.

Other options may be preferable for people who need transparent individual ingredient dosing for clinical comparison, are caffeine-sensitive (both guarana and green tea contain natural caffeine with undisclosed total content per serving), or expect rapid weight loss from a single supplement without accompanying lifestyle changes.

Before choosing any weight management supplement, consider whether you have discussed your goals with a healthcare provider, whether you understand the ingredient profile and dosing transparency, and whether the product fits within a realistic wellness plan. Your answers help determine which product characteristics matter most for your situation.

TrimX Pricing and Guarantee

According to pricing information displayed on the official TrimX website at the time this report was prepared, the product is offered in several multi-bottle supply options with per-bottle pricing that decreases in larger packages. The largest package represents approximately a 180-day supply with per-bottle pricing near $49 and free U.S. shipping, while a 90-day supply option is listed near $69 per bottle with free U.S. shipping, and a 60-day supply option is listed near $79 per bottle plus shipping. Multi-bottle packages are described as including bonus wellness resources. According to the company, all purchases are one-time payments with no subscriptions or automatic rebilling.

The company also states that purchases are accompanied by a 60-day satisfaction policy beginning on the date of purchase. Per the published terms, the company indicates that consumers should use the product for at least 30 days before initiating a return request by contacting the support team. It is worth reviewing the complete policy terms on the official website and retaining all purchase confirmation details.

Pricing and availability can change. Readers can view the current TrimX offer (official TrimX page) to verify current terms before purchasing.

What Consumers Should Know About Testimonials

The company’s website includes customer testimonials describing individual experiences with the product, attributed to named individuals with locations. Consumers should be aware that people who write reviews are self-selected — satisfied customers are more likely to post feedback than those with neutral or negative experiences. These individual experiences should not be interpreted as typical or guaranteed results.

As with any dietary supplement, outcomes depend on numerous personal factors including age, baseline health, dietary habits, activity level, and consistency of use. No supplement manufacturer can guarantee specific outcomes for individual consumers.

Consumer Verification Checklist

Verify individual ingredient dosages. TrimX does not disclose individual amounts per serving. If exact dosages matter to your evaluation, contact the manufacturer directly.

Separate ingredient research from product research. Published studies on individual compounds do not constitute clinical proof for the finished formula. Knowing the difference helps set realistic expectations.

Confirm caffeine content. Guarana and green tea both contain natural caffeine. Total caffeine per serving is not disclosed — if you manage caffeine intake, confirm this detail before use.

Review refund terms independently. Confirm guarantee conditions, the 30-day minimum use requirement, and processing timelines directly on the official website before purchasing.

Consult your healthcare provider. This is especially important if you take prescription medications, manage chronic conditions like diabetes or high blood pressure, or are navigating hormonal changes. The company’s own FAQ recommends showing the label to your doctor if you have a known medical condition.

Frequently Asked Questions

What is TrimX Drops?

TrimX is a dietary supplement in liquid drop form containing six active ingredients — Guarana Seed Extract, Green Tea, African Mango, Raspberry Ketones, L-Carnitine, and Gymnema Leaf Extract. According to the company, these ingredients are described as working together to support metabolism, appetite control, and energy.

Does TrimX contain caffeine?

Yes. Guarana Seed Extract and Green Tea both naturally contain caffeine. The specific caffeine content per serving is not disclosed on the product page.

Is TrimX FDA approved?

TrimX is a dietary supplement. Under current federal regulations, dietary supplements do not require FDA approval before being sold. According to the company, TrimX is manufactured in an FDA-registered facility — which relates to manufacturing standards, not product approval.

How do TrimX Drops work?

According to the company, TrimX is described as working on three fronts: accelerating metabolism through thermogenic ingredients, controlling hunger through compounds that act on satiety hormones, and optimizing fat transport for energy use through L-Carnitine. These are the company’s descriptions of the product’s intended mechanism.

What ingredients are in TrimX?

The published ingredient list includes Guarana Seed Extract, Green Tea, African Mango, Raspberry Ketones, L-Carnitine, and Gymnema Leaf Extract. Individual dosages per serving are not disclosed.

How long does TrimX take to work?

The company’s FAQ suggests the 6-bottle kit covering six months is ideal for consistent use. Individual timelines depend on factors including baseline health, dietary habits, and physical activity. These are the company’s descriptions, not guaranteed outcome timelines.

What is the TrimX return policy?

According to the company, TrimX purchases are accompanied by a 60-day satisfaction policy beginning on the date of purchase. The published terms indicate consumers should use the product for at least 30 days before initiating a return request through the company’s support email.

Is there a subscription?

According to the company, all purchases are one-time orders with no automatic renewals, hidden fees, or surprise charges.

Summary

TrimX Drops is marketed as a liquid thermogenic metabolism-support supplement containing six active botanical and nutrient ingredients. Several individual compounds in the formula have published research at the ingredient level. However, individual ingredient dosages per serving are not disclosed, and no published clinical trial has evaluated the finished product as formulated.

The company provides a 60-day satisfaction policy, one-time purchase pricing with no subscriptions, and states that the product is manufactured in an FDA-registered facility. Consumers who have completed their own research and want to review the full product details can do so. Complete product details, current pricing, and published terms are available — readers can view the current TrimX offer (official TrimX page) to review all company-published information.

Contact Information

For questions before or during the ordering process, according to the company’s website, TrimX offers customer support:

Email: contact@customercs.com
Phone: +1-866-637-2482

View the current TrimX offer (official TrimX page)

Disclaimers

Content and Consumer Information Disclaimer: This article is an independent informational overview and does not constitute medical, health, dietary, financial, or legal advice. All product details, ingredient information, pricing, and policy terms described in this article are stated as presented by the company on its publicly available website and product labeling. This content has not been independently audited or verified unless specifically noted. Readers are encouraged to verify all claims directly with the manufacturer and to consult a qualified healthcare professional before beginning any dietary supplement.

FDA Health Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

Professional Medical Disclaimer: This article is educational and does not constitute medical advice. TrimX is a dietary supplement, not a medication. If you are currently taking medications, have existing health conditions, are pregnant or nursing, or are considering any major changes to your health regimen, consult your physician before starting TrimX or any new supplement. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician’s guidance and approval.

Results May Vary: Individual results will vary based on factors including age, baseline health condition, lifestyle factors, consistency of use, genetic factors, current medications, and other individual variables. While some customers report improvements, results are not guaranteed. People who write reviews are self-selected — satisfied customers are more likely to post feedback than those with neutral or negative experiences.

FTC Affiliate Disclosure: This article contains affiliate links. If a product is purchased through these links, a commission may be earned at no additional cost to the buyer. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. All opinions and descriptions are based on published research and publicly available information.

Pricing Disclaimer: All prices, discounts, and promotional offers mentioned were accurate at the time of publication (March 2026) but are subject to change without notice. Always verify current pricing and terms on the official TrimX website before making your purchase.

Publisher Responsibility Disclaimer: The publisher of this article has made every effort to ensure accuracy at the time of publication. We do not accept responsibility for errors, omissions, or outcomes resulting from the use of the information provided. Readers are encouraged to verify all details directly with TrimX and their healthcare provider before making decisions.

CONTACT: Email: contact@customercs.com
Phone: +1-866-637-2482

TrimX Drops Metabolism Claims Evaluated: Latest Report About TrimX Liquid Thermogenic Formula Ingredient Research & Effectiveness for Men & Women




TrimX Drops Metabolism Claims Evaluated: Latest Report About TrimX Liquid Thermogenic Formula Ingredient Research & Effectiveness for Men & Women

A 2026 consumer research report examining TrimX Drops metabolism marketing claims, liquid thermogenic formulation, ingredient-level research, and key verification considerations for adults researching weight management supplements

Lakeland, FL, March 10, 2026 (GLOBE NEWSWIRE) — This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This article is an informational overview and does not constitute medical, health, or dietary advice. All product details described below are stated as presented by the company and should be verified directly on the official website before any purchasing decision. In this report, the term “effectiveness” refers strictly to how TrimX’s marketing language describes potential outcomes. It does not indicate that the finished product has been clinically proven effective, and no published clinical trial appears to evaluate TrimX Drops as a proprietary formula.

Consumer interest in metabolism-support supplements has grown significantly in recent years, particularly products marketed as thermogenic fat-burning formulas in liquid delivery formats. Online search activity around metabolism drops, thermogenic supplements, and liquid fat-burning formulas remains high across wellness and supplement research communities — driven largely by adults over 35 who feel stuck with stubborn weight despite genuine effort with diet and exercise.

One product generating increased online searches is TrimX Drops, a liquid supplement positioned by the company as a metabolic combination intended to support metabolism, influence fat storage signals, and help manage cravings. With that visibility come real questions — and those questions are worth examining in light of the available ingredient research and the company’s published claims.

This report evaluates what the company states, what ingredient-level research supports under controlled conditions, and where gaps remain between marketing language and product-level evidence. Readers can view the current TrimX offer (official TrimX page) to review the latest product information and company-published details.

Individual results vary. Dietary supplements are not substitutes for balanced nutrition, regular physical activity, or professional medical guidance. Consult a qualified healthcare provider before starting any new supplement regimen.

What Is TrimX

TrimX is a dietary supplement sold in liquid drop form. According to the company’s website, it is produced in the United States in an FDA-registered facility using naturally-derived ingredients without harmful artificial stimulants or chemical additives. The company states that all ingredients are tested for quality and safety.

The recommended use, per the company, is one or two droppers full daily — placed in the mouth and swallowed, preferably in the morning before breakfast. The product is sold exclusively through the official website, with payments processed through CartPanda. According to the company, all purchases are one-time orders with no automatic renewals, hidden fees, or surprise charges.

The published ingredient list includes six primary active compounds: Guarana Seed Extract, Green Tea, African Mango, Raspberry Ketones, L-Carnitine, and Gymnema Leaf Extract. Each is positioned by the company as serving a distinct metabolic function within the formula.

TrimX Marketing Claims vs. What Research Supports

The company’s marketing describes TrimX as targeting what it calls the root causes of stubborn fat, persistent bloating, and uncontrolled hunger. The product page presents a narrative around metabolic slowdown and positions TrimX as a formula that works on three fronts: accelerating metabolism through thermogenics, controlling hunger through satiety-related compounds, and optimizing fat transport for energy use.

These claims reflect the product’s marketing narrative rather than conclusions from clinical trials evaluating the finished formulation. Understanding the distinction matters if you’re trying to make an informed decision.

The individual ingredients in TrimX do have varying levels of published research behind them — but that research examined specific compounds at known dosages under controlled conditions, not TrimX’s specific liquid formula as a finished product.

For example, green tea catechins (particularly EGCG) have a substantial research base. A 2009 meta-analysis in the International Journal of Obesity found that catechin-caffeine mixtures had a modest positive effect on weight management. However, effective study dosages typically involved 270 to 600 mg of EGCG daily. TrimX does not disclose the exact amount of green tea extract or EGCG per serving.

Similarly, African Mango seed extract was associated with improvements in body weight in a 2009 randomized trial published in Lipids in Health and Disease — but at a specific dosage of 150 mg twice daily. Whether TrimX provides a comparable amount is not stated on the product page.

Consumers researching TrimX online often look for information about its ingredients, metabolism-related marketing claims, and how the formula compares with existing ingredient research. What matters most here is understanding that marketing language referencing metabolic research describes ingredient-level findings, not product-level clinical outcomes verified through independent testing.

TrimX Ingredient Profile

Based on the company’s published product information, TrimX contains six active ingredients. Here is what the company describes and what published research indicates for each compound individually.

Guarana Seed Extract: The company describes this as a natural thermogenic that speeds up metabolism and provides sustained energy. Guarana contains caffeine, which has well-documented short-term effects on metabolic rate in published literature. The specific caffeine content per dropper is not disclosed.

Green Tea: The company states that green tea catechins help the body access stored fat, especially in the abdominal region. Published research supports associations between green tea catechins and fat oxidation, though effective study dosages typically exceed what a multi-ingredient liquid formula would deliver without disclosed amounts.

African Mango: The company positions this as a natural appetite suppressant that works through leptin, the satiety hormone. Published research on Irvingia gabonensis does exist, though studies used specific dosages of a characterized extract.

Raspberry Ketones: The company describes these as activating lipolysis — the process of breaking down fat. Published human research on raspberry ketones in isolation is extremely limited. Most studies have used multi-ingredient formulations, making it difficult to isolate raspberry ketone-specific effects.

L-Carnitine: The company describes this as the fat transporter that carries fatty acids to the mitochondria for energy production. L-Carnitine has a stronger published research base than most ingredients in this formula. A 2016 systematic review in Obesity Reviews found modest associations with weight loss — though study dosages typically ranged from 1,000 to 3,000 mg daily.

Gymnema Leaf Extract: The company calls this the sugar destroyer, referencing effects on glucose absorption and sweet taste perception. Gymnema sylvestre has been studied primarily for blood sugar regulation, with most evidence coming from animal models or small human trials.

The key consideration across all six ingredients is that TrimX does not disclose individual dosages per serving. Without knowing exact amounts, you cannot directly compare what is in each dropper against the dosages used in published research studies. This is not unique to TrimX — many liquid supplements use similar labeling — but it is worth factoring into your evaluation.

The Liquid Delivery Format

TrimX is marketed in liquid drop form, and the company’s materials suggest advantages over capsules or tablets. Liquid supplement formats are sometimes marketed as offering faster absorption. There is some published basis for this concept in certain contexts — but bioavailability depends on the specific compound, formulation vehicle, and individual digestive physiology.

No published study appears to evaluate TrimX’s specific liquid formula compared against alternative delivery formats for the same ingredients. The liquid format is a distinguishing feature in the supplement market, but the absorption advantage claim has not been validated for this specific product.

What Would Be Required to Prove Effectiveness

This is one of the most practical questions you can ask about any supplement. For a dietary supplement to demonstrate effectiveness through clinical evidence, the standard includes a randomized, placebo-controlled trial using the finished product at its actual dosage — with disclosed formulation, defined endpoints, and a representative study population. Results would be published in a peer-reviewed journal.

As of this writing, no published clinical trial appears to have evaluated TrimX Drops as a finished proprietary formula. The research cited in the product’s marketing pertains to individual compounds tested in isolation, often at dosages that may differ from what the liquid formula delivers. Understanding this distinction helps you make a purchasing decision based on the actual evidence landscape.

Who May Be Interested in This Type of Product

Based on the product’s positioning and ingredient profile, TrimX may be of interest to adults exploring plant-based metabolism-support supplements in liquid form as one component of a broader wellness approach that includes balanced nutrition and regular physical activity.

TrimX may align well with people who prefer liquid supplement formats over capsules, want a caffeine-containing thermogenic option with natural energy sources, or are looking for appetite management support as part of a broader dietary strategy.

Other options may be preferable for people who need transparent individual ingredient dosing for clinical comparison, are caffeine-sensitive (both guarana and green tea contain natural caffeine with undisclosed total content per serving), or expect rapid weight loss from a single supplement without accompanying lifestyle changes.

Before choosing any weight management supplement, consider whether you have discussed your goals with a healthcare provider, whether you understand the ingredient profile and dosing transparency, and whether the product fits within a realistic wellness plan. Your answers help determine which product characteristics matter most for your situation.

TrimX Pricing and Guarantee

According to pricing information displayed on the official TrimX website at the time this report was prepared, the product is offered in several multi-bottle supply options with per-bottle pricing that decreases in larger packages. The largest package represents approximately a 180-day supply with per-bottle pricing near $49 and free U.S. shipping, while a 90-day supply option is listed near $69 per bottle with free U.S. shipping, and a 60-day supply option is listed near $79 per bottle plus shipping. Multi-bottle packages are described as including bonus wellness resources. According to the company, all purchases are one-time payments with no subscriptions or automatic rebilling.

The company also states that purchases are accompanied by a 60-day satisfaction policy beginning on the date of purchase. Per the published terms, the company indicates that consumers should use the product for at least 30 days before initiating a return request by contacting the support team. It is worth reviewing the complete policy terms on the official website and retaining all purchase confirmation details.

Pricing and availability can change. Readers can view the current TrimX offer (official TrimX page) to verify current terms before purchasing.

What Consumers Should Know About Testimonials

The company’s website includes customer testimonials describing individual experiences with the product, attributed to named individuals with locations. Consumers should be aware that people who write reviews are self-selected — satisfied customers are more likely to post feedback than those with neutral or negative experiences. These individual experiences should not be interpreted as typical or guaranteed results.

As with any dietary supplement, outcomes depend on numerous personal factors including age, baseline health, dietary habits, activity level, and consistency of use. No supplement manufacturer can guarantee specific outcomes for individual consumers.

Consumer Verification Checklist

Verify individual ingredient dosages. TrimX does not disclose individual amounts per serving. If exact dosages matter to your evaluation, contact the manufacturer directly.

Separate ingredient research from product research. Published studies on individual compounds do not constitute clinical proof for the finished formula. Knowing the difference helps set realistic expectations.

Confirm caffeine content. Guarana and green tea both contain natural caffeine. Total caffeine per serving is not disclosed — if you manage caffeine intake, confirm this detail before use.

Review refund terms independently. Confirm guarantee conditions, the 30-day minimum use requirement, and processing timelines directly on the official website before purchasing.

Consult your healthcare provider. This is especially important if you take prescription medications, manage chronic conditions like diabetes or high blood pressure, or are navigating hormonal changes. The company’s own FAQ recommends showing the label to your doctor if you have a known medical condition.

Frequently Asked Questions

What is TrimX Drops?

TrimX is a dietary supplement in liquid drop form containing six active ingredients — Guarana Seed Extract, Green Tea, African Mango, Raspberry Ketones, L-Carnitine, and Gymnema Leaf Extract. According to the company, these ingredients are described as working together to support metabolism, appetite control, and energy.

Does TrimX contain caffeine?

Yes. Guarana Seed Extract and Green Tea both naturally contain caffeine. The specific caffeine content per serving is not disclosed on the product page.

Is TrimX FDA approved?

TrimX is a dietary supplement. Under current federal regulations, dietary supplements do not require FDA approval before being sold. According to the company, TrimX is manufactured in an FDA-registered facility — which relates to manufacturing standards, not product approval.

How do TrimX Drops work?

According to the company, TrimX is described as working on three fronts: accelerating metabolism through thermogenic ingredients, controlling hunger through compounds that act on satiety hormones, and optimizing fat transport for energy use through L-Carnitine. These are the company’s descriptions of the product’s intended mechanism.

What ingredients are in TrimX?

The published ingredient list includes Guarana Seed Extract, Green Tea, African Mango, Raspberry Ketones, L-Carnitine, and Gymnema Leaf Extract. Individual dosages per serving are not disclosed.

How long does TrimX take to work?

The company’s FAQ suggests the 6-bottle kit covering six months is ideal for consistent use. Individual timelines depend on factors including baseline health, dietary habits, and physical activity. These are the company’s descriptions, not guaranteed outcome timelines.

What is the TrimX return policy?

According to the company, TrimX purchases are accompanied by a 60-day satisfaction policy beginning on the date of purchase. The published terms indicate consumers should use the product for at least 30 days before initiating a return request through the company’s support email.

Is there a subscription?

According to the company, all purchases are one-time orders with no automatic renewals, hidden fees, or surprise charges.

Summary

TrimX Drops is marketed as a liquid thermogenic metabolism-support supplement containing six active botanical and nutrient ingredients. Several individual compounds in the formula have published research at the ingredient level. However, individual ingredient dosages per serving are not disclosed, and no published clinical trial has evaluated the finished product as formulated.

The company provides a 60-day satisfaction policy, one-time purchase pricing with no subscriptions, and states that the product is manufactured in an FDA-registered facility. Consumers who have completed their own research and want to review the full product details can do so. Complete product details, current pricing, and published terms are available — readers can view the current TrimX offer (official TrimX page) to review all company-published information.

Contact Information

For questions before or during the ordering process, according to the company’s website, TrimX offers customer support:

Email: contact@customercs.com
Phone: +1-866-637-2482

View the current TrimX offer (official TrimX page)

Disclaimers

Content and Consumer Information Disclaimer: This article is an independent informational overview and does not constitute medical, health, dietary, financial, or legal advice. All product details, ingredient information, pricing, and policy terms described in this article are stated as presented by the company on its publicly available website and product labeling. This content has not been independently audited or verified unless specifically noted. Readers are encouraged to verify all claims directly with the manufacturer and to consult a qualified healthcare professional before beginning any dietary supplement.

FDA Health Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

Professional Medical Disclaimer: This article is educational and does not constitute medical advice. TrimX is a dietary supplement, not a medication. If you are currently taking medications, have existing health conditions, are pregnant or nursing, or are considering any major changes to your health regimen, consult your physician before starting TrimX or any new supplement. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician’s guidance and approval.

Results May Vary: Individual results will vary based on factors including age, baseline health condition, lifestyle factors, consistency of use, genetic factors, current medications, and other individual variables. While some customers report improvements, results are not guaranteed. People who write reviews are self-selected — satisfied customers are more likely to post feedback than those with neutral or negative experiences.

FTC Affiliate Disclosure: This article contains affiliate links. If a product is purchased through these links, a commission may be earned at no additional cost to the buyer. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. All opinions and descriptions are based on published research and publicly available information.

Pricing Disclaimer: All prices, discounts, and promotional offers mentioned were accurate at the time of publication (March 2026) but are subject to change without notice. Always verify current pricing and terms on the official TrimX website before making your purchase.

Publisher Responsibility Disclaimer: The publisher of this article has made every effort to ensure accuracy at the time of publication. We do not accept responsibility for errors, omissions, or outcomes resulting from the use of the information provided. Readers are encouraged to verify all details directly with TrimX and their healthcare provider before making decisions.

CONTACT: Email: contact@customercs.com
Phone: +1-866-637-2482

The Leave-of-Absence Trap in Sham Peer Review Discussed in the Journal of American Physicians and Surgeons




The Leave-of-Absence Trap in Sham Peer Review Discussed in the Journal of American Physicians and Surgeons

TUCSON, Ariz., March 10, 2026 (GLOBE NEWSWIRE) — The latest addition to the hospital sham peer review playbook for removing undesired physicians is the leave-of-absence trap, writes Lawrence R. Huntoon, M.D, Ph.D., in the spring issue of the Journal of American Physicians and Surgeons. The technique depends heavily on coercion and deception.

Typically, a targeted physician meets with hospital leadership behind closed doors and is told he must either “voluntarily” take a leave of absence while the hospital conducts an investigation to determine whether any further action is needed or he will be subject to an immediate summary suspension. The physician is often led to believe that the leave of absence will not result in a highly damaging report in the National Practitioner Data Bank (NPDB), Dr. Huntoon states.

However, since a leave of absence virtually always means that a physician agrees not to exercise privileges, it is treated as a resignation while under investigation, which is immediately reportable, Dr. Huntoon cautions.

He notes that hospitals may use this tactic when they fear that the physician might be exonerated in an honest peer-review procedure. If the physicians’ privileges are not reinstated upon return from leave, there is no more due process.

As an alternative, Dr. Huntoon suggests that the physician might simply take a vacation. “The physician’s attorney should seek to negotiate this alternative, while making sure that there is no agreement not to exercise privileges during vacation.”

He adds: “A vacation would also give the physician time to gather together resources, materials, documents, and expert opinions; set up a ‘war room’ in his home; and discuss strategy with his attorney to prepare for the fight of his life.”

In correspondence with the NPDB, Dr. Huntoon confirmed that if a vacation does not restrict privileges, it is not reportable.

He concludes that “the physician’s attorney needs to be involved early on and needs to be aggressive in advocating for an alternative that will not irreparably harm his client…. Due process and fundamental fairness require that a physician not be punished prior to a…fair hearing and appeals.”

The Journal of American Physicians and Surgeons is published by the Association of American Physicians and Surgeons (AAPS), a national organization representing physicians in all specialties since 1943.

Contact: Jane M. Orient, M.D., (520) 323-3110, janeorientmd@gmail.com

Adverse Effects of COVID Vaccine on Skin Are Underrated, according to the Journal of American Physicians and Surgeons




Adverse Effects of COVID Vaccine on Skin Are Underrated, according to the Journal of American Physicians and Surgeons

TUCSON, Ariz., March 10, 2026 (GLOBE NEWSWIRE) — The skin-related adverse effects of COVID vaccines have been dismissed as “irrelevant” by experts and overlooked by the public, writes Jane M. Orient, M.D., in the spring issue of the Journal of American Physicians and Surgeons.

While the lay public may be unaware of the significance of skin pathologies, their neglect by regulators was unexpected because they know that the dangers exceed mere cosmetic issues, she states.

The article summarizes the manifold functions of this critical organ, which is not a mere protective barrier but a crucial super-organ. As a part of recently discovered cutaneous-immuno-neuro-endocrine (CINE) system, skin coordinates immune responses, thermoregulation, and chemical homeostasis. It carries out neuro-endocrine functions via production of neuropeptides, neurotransmitters, and steroid hormones including sex hormones and vitamin D3.

“The potential interference of mRNA vaccine with those crucial functions of the skin may have very serious systemic consequences with grave implication for patients’ general health status,” Dr. Orient states.

The skin also serves as a “diagnostic display” for systemic illness, she adds, and in vaccinated patients might signal systemic adverse reactions such as autoimmune conditions.

Historically, traditional vaccines have triggered serious cutaneous reactions. The mRNA platform vaccines introduce new harmful mechanisms, such as the use of lipid nanoparticles and polyethylene glycol, she writes.

Global pharmacovigilance databases, such as the American Academy of Dermatology (AAD) COVID-19 Registry and the International League of Dermatological Societies (ILDS) have provided valuable insights into cutaneous side effects of mRNA vaccines. Unfortunately, the concerns they raise have been dismissed by officials, Dr. Orient observes.

The fact that the mRNA platform was implemented despite warning signs of cutaneous and other serious risks “defies rational explanation.” Future research of risk/benefits profiles of vaccines should be driven by objectivity, not by the biased desire to “decrease vaccine hesitancy.” Any vaccines with proven unfavorable risk/benefit ratio should be removed from the market. “Until then, physicians who encounter cutaneous signs in vaccinated patients should exert diagnostic due diligence.” she concludes.

The Journal of American Physicians and Surgeons is published by the Association of American Physicians and Surgeons (AAPS), a national organization representing physicians in all specialties since 1943.

Contact: Jane M. Orient, M.D., (520) 323-3110, janeorientmd@gmail.com

To Restore Trust, Doctors Need to Re-commit to the Oath of Hippocrates, according to the Journal of American Physicians and Surgeons




To Restore Trust, Doctors Need to Re-commit to the Oath of Hippocrates, according to the Journal of American Physicians and Surgeons

TUCSON, Ariz., March 10, 2026 (GLOBE NEWSWIRE) — The medical profession has traded its birthright for a mess of pottage called evidence-based medicine, writes Stephen Hughes, M.D., in the spring issue of the Journal of American Physicians and Surgeons. Dr. Hughes is a resident physician in internal medicine and pediatrics in South Carolina.

At the time the Hippocratic Oath was first penned and sworn, it represented “a definitive break with the surrounding culture and values of the medical establishment,” Dr. Hughes states. “It is a call to reform, with the fundamental recognition that the purpose of medicine is ‘to help the sick.’”

“If followed generally, these precepts would have prevented much of the chaos of the COVID crisis, in which physicians refused to see the sick in their clinics and instead abandoned them to the emergency departments, blindly followed sham guidelines, ignored safe and effective early treatments borne out by clinical experience, and supported draconian and unethical requirements for mass COVID ‘vaccination.’ The loss of society’s trust is a self-inflicted wound,” he writes.

Dr. Hughes reminds us that medical experimentation, abortion, euthanasia, and sexual coercion are all specifically named and prohibited by the Oath. Those vices that characterized medicine in the time of Hippocrates have emerged again as “the defiling blemishes of our age,” he observes.

The Oath of Hippocrates lays out, in timeless form, a vision of medicine bounded by a set of moral commitments pledged to each of the physician’s patients. Hippocratic physicians took their Oath at the beginning of their training, “Successfully restoring morals and professionalism to medicine necessitates the successful transfer of Hippocratic medicine to the next generation of future physicians,” he concludes.

The Journal of American Physicians and Surgeons is published by the Association of American Physicians and Surgeons (AAPS), a national organization representing physicians in all specialties since 1943.

CONTACT: Contact: Jane M. Orient, M.D., (520) 323-3110, janeorientmd@gmail.com